Adoptive immunotherapy with engineered T cells expressing and HLA-A2 restricted affinity-enhanced TCR for LAGE-1 and NY-ESO-1 in patients with multiple myeloma following auto-SCT
Aaron P. Rapoport(University of Maryland, Baltimore), Edward A. Stadtmauer(California University of Pennsylvania), Dan T. Vogl(California University of Pennsylvania), Brendan M. Weiss(California University of Pennsylvania), Gwendolyn Binder-Scholl(Adaptimmune (United Kingdom)), Dominic Smethurst(Adaptimmune (United Kingdom)), Jeffrey Finklestein(California University of Pennsylvania), Irina Kulikovskaya(California University of Pennsylvania), Minnal Gupta(California University of Pennsylvania), Joanna E. Brewer(Adaptimmune (United Kingdom)), Alan Bennett(Adaptimmune (United Kingdom)), Andrew B. Gerry(Adaptimmune (United Kingdom)), Nick Pumphrey(Adaptimmune (United Kingdom)), Helen K. Tayton-Martin(Adaptimmune (United Kingdom)), Lilliam Ribeiro(Adaptimmune (United Kingdom)), Ashraf Badros(University of Maryland, Baltimore), Saul Yanovich(University of Maryland, Baltimore), Görgün Akpek(University of Maryland, Baltimore), Naseem Kerr(California University of Pennsylvania), Sunita Philip(University of Maryland, Baltimore), Sandra Westphal(University of Maryland, Baltimore), Levine L Bruce(California University of Pennsylvania), Bent K. Jakobsen(Adaptimmune (United Kingdom)), Carl H. June(California University of Pennsylvania), Michael Kalos(University of Pennsylvania)
Cited by 1Open Access
Abstract
Meeting abstracts We report on a 26 patient phase I/II clinical trial ([NCT01352286][1]) to investigate the safety, feasibility and anti-tumor activity of T cells engineered to express an affinity-enhanced TCR that recognizes the NY-ESO-1/LAGE-1 peptide complex HLA-A*0201-SLLMWITQC. Patients with
Related Papers
No related papers found
Powered by citation graph analysis